Clinical Trial Protocol
Iranian Registry of Clinical Trials

17 Sep 2026

Evaluation of Typical Antipsychotic Augmentation with citalopram in reduction of Negative Symptoms in Inpatient schizophrenia in Ahvaz Golestan Hospital 1389

Protocol summary

Summary

This study is conducted to evaluate negative symptoms reduction of schizophrenia in inpatients on typical antipsychotic augmentation with citalopram in Ahvaz Golestan Hospital 1389. This study is a randomized double blind clinical trial conducted on 40 patients with schizophrenia, meeting the eligibility criteria. The patients will be randomly assigned to receive either citalopram (20 mg for first week and 40 mg for the next weeks) or placebo. Depression is rule out by Hamilton depression rating scale. PANSS is used to assess negative and positive symptoms at the baseline and 3rd and 6th weeks.

General information

Acronym

IRCT registration information

IRCT registration number: **IRCT138902113843N1**
Registration date: **2010-12-01, 1389/09/10**
Registration timing: **registered_while_recruiting**

Last update:
Update count: **0**

Registration date

2010-12-01, 1389/09/10

Registrant information

Name

Niloufar Khajeddin

Name of organization / entity

Ahvaz Jundishapor University of Medical Sciences

Country

Iran (Islamic Republic of)

Phone

+98 61 1374 3038

Email address

khajeddin@ajums.ac.ir

Recruitment status

Recruitment complete

Funding source

Ahvaz Jundishapur University of Medical Sciences

Expected recruitment start date

2010-08-23, 1389/06/01

Expected recruitment end date

2011-02-20, 1389/12/01

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Evaluation of Typical Antipsychotic Augmentation with citalopram in reduction of Negative Symptoms in Inpatient schizophrenia in Ahvaz Golestan Hospital 1389

Public title

Negative symptom treatment in schizophrenia disorder

Purpose

Treatment

Inclusion/Exclusion criteria

Inclusion criteria: Diagnosis of schizophrenia based on DSM-IV TR structured clinical interview by a psychiatrist (faculty member and psychiatry resident), prominent negative Symptoms (PANSS negative score more than 15) , total PANSS score more than 50, no liver disease, no treatment with ECT within 6 months, age between 18 and 70, illness duration at least 1 year. Exclusion criteria: depressive disorder based on DSM-IV TR interview and more than 17 score by Hamilton depression rating scale , MR, schizoaffective, Bipolar disorder, Neurological disorders , severe organic disease for example IHD or CHF, treatment with anti depressants or lithium, deaf

mute, substance abuse within 1 month ago (except nicotine and caffeine), use of any other drugs which had interactions with this study, active suicidal or homicidal thoughts, breast feeding or pregnancy, past history of allergy or complications with study medication, EPS, at least 3 months interval with the last dose of long term antipsychotic medication

Age
From **18 years** old to **70 years** old

Gender
Both

Phase
N/A

Groups that have been masked
No information

Sample size
Target sample size: **40**

Randomization (investigator's opinion)
Randomized

Randomization description

Blinding (investigator's opinion)
Double blinded

Blinding description

Placebo
Used

Assignment
Parallel

Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee
Ahvaz Jundishapor University of Medical Sciences

Street address
Golestan Blvd., Ahvaz

City
Ahvaz

Postal code
0098

Approval date
empty

Ethics committee reference number
348/20/8/پ

Health conditions studied

1

Description of health condition studied
Schizophrenia disorder

ICD-10 code
F20

ICD-10 code description
paranoid schizophrenia, hebephrenic schizophrenia, catatonic schizophrenia ,undiffrentiated schizophrenia

Primary outcomes

1

Description
positive symptoms, negative symptoms, general psychopatology

Timepoint
Days 0, 21, and 42

Method of measurement
PANSS scale

Secondary outcomes

1

Description
Extrapyramidal side effects

Timepoint
Days 0, 21, and 42

Method of measurement
SIMPSON ANGUS SCALE

Intervention groups

1

Description
citalopram 20mg on the 1st till 7th days, then 40mg on 8th till 42 days.

Category
Treatment - Drugs

2

Description
placebo 1tablet on the 1st till 7th days, then 2 tablets in 8th till 42 days.

Category
Treatment - Drugs

Recruitment centers

1

Recruitment center

Name of recruitment center
Golestan hospital

Full name of responsible person
Dr Niloufar Khajeddin

Street address
Golestan hospital, psychiatry department

City
Ahvaz

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Ahvaz Jundishapur University of Medical Sciences

Full name of responsible person

Dr Niloufar Khajeddin

Street address

Golestan hospital, psychiatry department

City

Ahvaz

Grant name

2-124500

Grant code / Reference number

10506

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Ahvaz Jundishapur University of Medical Sciences

Proportion provided by this source

100

Public or private sector

empty

Domestic or foreign origin

empty

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

empty

Person responsible for general inquiries

Contact

Name of organization / entity

Ahvaz Jundishapor University of Medical Sciences

Full name of responsible person

Dr Niloufar Khajeddin

Position

Assistant professor of Psychiatry

Other areas of specialty/work

Street address

Golestan Blv

City

Ahvaz

Postal code

Phone

+98 61 1374 3038

Fax

+98 61 1374 3038

Email

khajeddinn@gmail.com

Web page address

www.ajums.ac.ir

Person responsible for scientific inquiries

Contact

Name of organization / entity

Ahvaz Jundishapor University of Medical Sciences

Full name of responsible person

Dr Niloufar Khajeddin

Position

Assistant professor of psychiatry

Other areas of specialty/work

Street address

Golestan Blv

City

Ahvaz

Postal code

Phone

+98 61 1374 3038

Fax

+98 61 1374 3038

Email

khajeddinn@gmail.com

Web page address

www.ajums.ac.ir

Person responsible for updating data

Contact

Name of organization / entity

Ahvaz Jundishapor University of Medical Sciences

Full name of responsible person

Dr Niloufar Khajeddin

Position

Assistant professor of psychiatry

Other areas of specialty/work

Street address

Golestan Blv

City

Ahvaz

Postal code

Phone

+98 61 1374 3038

Fax

+98 61 1374 3038

Email

khajeddinn@gmail.com

Web page address

www.ajums.ac.ir

Sharing plan

Deidentified Individual Participant Data Set (IPD)

empty

Study Protocol

empty

Statistical Analysis Plan

empty

Informed Consent Form

empty

Clinical Study Report

empty

Analytic Code

empty

Data Dictionary

empty